Last reviewed · How we verify
NCT07393633
Assessing Whole-body Metabolism in Gynecologic Cancers in Response to a Single Chemotherapy Cycle and/ or Immunotherapy
trial in Gynecologic Cancers in 43 participants. Completed in 24 January 2026.
4 April 2025
Quick facts
| Lead sponsor | University of Tennessee Graduate School of Medicine |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 43 |
| Start date | 1 August 2024 |
| Primary completion | 4 April 2025 |
| Estimated completion | 24 January 2026 |
| Sites | 1 location across United States |
Conditions studied
- Gynecologic Cancers — all drugs for Gynecologic Cancers →
Sponsor
University of Tennessee Graduate School of Medicine
Who can join
18 and older, female only, with Gynecologic Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is well established that cancer cells have fundamentally altered metabolism, which contributes to tumorigenicity and malignancy. For years, research findings supported that the universal property of all cancer cells was to increase glycolytic flux for anaerobic glycolysis (i.e., Warburg effect), which was accepted as the dominant pathway for energy metabolism. Fortunately, by understanding these changes in cellular metabolism multiple new approaches to cancer therapy, focused on reprogramming the energy metabolism of the cell. Recently, further investigation in the field found that cancer cells exhibit multiple alterations in metabolic pathways, not only glycolysis. Alterations in lipid metabolism in cancer cells have recently been recognized as potential targets for therapeutic interventions due to its role in cellular proliferation, energy storage, and the generation of signaling molecules. Numerous cancer types can rely on lipids as an energy source, increasing fatty acid synthesis and degradation to promote proliferation and metastasis. Several therapeutic agents utilized in gynecologic malignancies impact lipid metabolism. The objective of the proposed study will be to determine the impact of cancer directed therapy on the lipid metabolism of non-malignant tissues. No study to date has assessed whole-body lipid metabolism in patients undergoing chemotherapy (i.e. cytotoxic chemotherapy and/or immunotherapy). These novel findings will provide crucial knowledge about the dysregulation of whole-body metabolism in patients receiving chemotherapy for treatment of gynecologic cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07393633
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gynecologic Cancers
Currently open trials in the same condition.
- NCT07327125 — Effect of Skin Closure Techniques on Body Image in Women Undergoing Gynecologic Surgery · NA · recruiting
- NCT07121738 — A Prospective Study of a Lifestyle Medicine Survivorship Program for Patients With Gynecologic Cancer · NA · recruiting
- NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
- NCT06920342 — Attitudes to Gynae Oncology Care Location - GRACEFUL · recruiting
- NCT06904339 — Communication About Sexual Health in Gynecologic Cancer · NA · recruiting
Other University of Tennessee Graduate School of Medicine trials
Trials by the same sponsor.
- NCT07223437 — REVASC-PAD: REstricted VASCular Exercise for Peripheral Arterial Disease - A Feasibility Study at University of Tennesse · NA · not yet recruiting
- NCT07214012 — Planning Together: A Couple-based, Multi-level Prenatal Contraceptive Education Program for Economically Marginalized Fa · NA · not yet recruiting
- NCT07205068 — Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and P · NA · recruiting
- NCT06953635 — Quadratus Lumborum Versus Placebo in Open Ventral Hernia Repair · NA · not yet recruiting
- NCT07153614 — Efficacy of Perioperative Opioid Sparing Techniques on Time to Initiation of Chemotherapy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07393633 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Tennessee Graduate School of Medicine
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07393633.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing